A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT03082508

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
LoneStar Heart, Inc. (from the registry)
Registry
  • NCT NCT03082508
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03082508. Randomized; single masking; primary purpose treatment. Start 2017-08 (anticipated); primary completion 2020-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
Acronym
AUGMENT-HFII
Condition
Heart Failure
Condition
Dilated Cardiomyopathy
Intervention (Device)
Algisyl
Intervention (Drug)
Standard Medical Therapy
Lead sponsor
LoneStar Heart, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03082508
Content hash
ff738b5c925c0443d7afef5d1b39b0efa44600f75080db413462332bc5247302